Close Menu

NEW YORK (GenomeWeb) — Singapore-based Lucence Diagnostics and NovogeneAIT Genomics Singapore announced today that they have partnered to develop next-generation sequencing-based tests for precision cancer treatment for the Asian market.

According to the partners, the tests will be designed to analyze the genetics of cancer tissue to help personalize a patient's treatment regimen and will focus on cancers prevalent in Asia. Additional terms of the deal were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Mar
18
Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

Mar
29
Sponsored by
Thermo Fisher Scientific

Global genetic surveillance is vital for understanding the evolution of viral pathogens and monitoring for changes in transmissibility, virulence, disease pathology, and impact on the efficacy of diagnostic tests, therapeutics, and vaccines.

Mar
31
Sponsored by
MilliporeSigma

This webinar will outline the development and commercialization journey of a novel CRISPR-based SARS-CoV-2 test.